Akero The First To Show Fibrosis Improvement In Cirrhotic MASH
The FGF21 analog is the first metabolic dysfunction-associated steatohepatitis drug to demonstrate benefit in cirrhotic patients. Several FGF21 agents are being tested in MASH.
The FGF21 analog is the first metabolic dysfunction-associated steatohepatitis drug to demonstrate benefit in cirrhotic patients. Several FGF21 agents are being tested in MASH.